Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery

Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery




Suono Bio, Inc. Announces Exclusive Patent License with MIT for Portfolio of Granted IP Covering Formulation-Independent Drug Delivery

FOXBOROUGH, Mass.–(BUSINESS WIRE)–Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has entered into an exclusive world-wide patent license with Massachusetts Institute of Technology (MIT), Brigham and Woman’s Hospital, and Massachusetts General Hospital. The associated patents broadly cover foundational elements for the rapid, targeted delivery of drugs, including gene therapies, throughout the gastrointestinal tract.

Suono Bio is advancing and expanding on technology originally developed in the laboratory of Institute Professor Robert Langer at MIT to facilitate rapid, local administration of therapeutics to treat serious diseases.

“This IP portfolio, including granted patents originally developed by Professor Robert Langer’s laboratory allows Suono Bio to build upon these insights to develop patient-ready treatments as we get set for clinical testing.” “The patents included in this license, along with several other patent applications filed by Suono Bio, are part of an expanding and comprehensive portfolio forming the foundation for our novel treatments,” said Dr. Carl Schoellhammer, Co-founder and director.

“This license which includes the recently granted US patent number 11,185,626 is key in our comprehensive program to develop the technology, advance to clinical stage, and ultimately commercialization,” said Scott Kellogg, CEO.

The company was founded by Robert Langer and Giovanni Traverso, a gastroenterologist and biomedical engineer from the Department of Mechanical Engineering, MIT and Brigham and Women’s Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. Publications on the technology have appeared in Nature, Gastroenterology, and Science Translational Medicine.

ABOUT SUONO BIO

Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bio’s platform enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit www.suonobio.com.

Contacts

Carl Schoellhammer cms@suonobio.com